Multi-pathway neuroprotective effects of a novel salidroside derivative SHPL-49 against acute cerebral ischemic injury.

[1]  Dafa Shi,et al.  Neuroprotective and Angiogenesis Effects of Levetiracetam Following Ischemic Stroke in Rats , 2021, Frontiers in Pharmacology.

[2]  Chen Jiang,et al.  Recent advances in nanomedicines for the treatment of ischemic stroke , 2020, Acta pharmaceutica Sinica. B.

[3]  J. E. Lee,et al.  Lipid Emulsion Improves Functional Recovery in an Animal Model of Stroke , 2020, International journal of molecular sciences.

[4]  Yulong Bai,et al.  A Review of Exercise-Induced Neuroplasticity in Ischemic Stroke: Pathology and Mechanisms , 2020, Molecular Neurobiology.

[5]  Chunjie Wu,et al.  Hydroxy-α-sanshool Possesses Protective Potentials on H2O2-Stimulated PC12 Cells by Suppression of Oxidative Stress-Induced Apoptosis through Regulation of PI3K/Akt Signal Pathway , 2020, Oxidative medicine and cellular longevity.

[6]  Miao Xie,et al.  β-Asarone Exerts Antioxidative Effects on H2O2-Stimulated PC12 Cells by Activating Nrf2/HO-1 Pathway , 2020, Neurochemical Research.

[7]  Ruixiang Li,et al.  Neuroprotective effect of salvianolate on cerebral ischaemia-reperfusion injury in rats by inhibiting the Caspase-3 signal pathway. , 2020, European journal of pharmacology.

[8]  Jun Wang,et al.  Improvement in mitochondrial function underlies the effects of ANNAO tablets on attenuating cerebral ischemia-reperfusion injuries. , 2020, Journal of ethnopharmacology.

[9]  Hong Shi,et al.  Anti-inflammatory effects of Rhodiola rosea L.: A review. , 2019, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[10]  H. Tabassum,et al.  Ischemic stroke and mitochondria: mechanisms and targets , 2019, Protoplasma.

[11]  D. Djuric,et al.  The Effects of Folic Acid Administration on Cardiac Oxidative Stress and Cardiovascular Biomarkers in Diabetic Rats , 2019, Oxidative medicine and cellular longevity.

[12]  F. Sun,et al.  MicroRNA-365 Knockdown Prevents Ischemic Neuronal Injury by Activating Oxidation Resistance 1-Mediated Antioxidant Signals , 2019, Neuroscience Bulletin.

[13]  Tao Xu,et al.  Salidroside represses proliferation, migration and invasion of human lung cancer cells through AKT and MEK/ERK signal pathway , 2019, Artificial cells, nanomedicine, and biotechnology.

[14]  Preeti Singh.  Molecular Pathways of Ischemic Stroke and Advanced Therapeutic Strategies , 2018, International Journal of Science, Technology & Society.

[15]  Zhenhua Zhou,et al.  Advances in stroke pharmacology , 2018, Pharmacology & therapeutics.

[16]  Xiaolin Xu,et al.  Neuroprotective effects of salidroside administration in a mouse model of Alzheimer's disease. , 2018, Molecular medicine reports.

[17]  M. Tymianski,et al.  Discovery and development of NA-1 for the treatment of acute ischemic stroke , 2018, Acta Pharmacologica Sinica.

[18]  J. Attia,et al.  Reperfusion therapy in acute ischemic stroke: dawn of a new era? , 2018, BMC Neurology.

[19]  J. Dekker,et al.  A randomised controlled multimodal intervention trial in patients with ischaemic stroke in Shandong, China: design and rationale , 2017, The Lancet.

[20]  Huazi Xu,et al.  Salidroside attenuates neuroinflammation and improves functional recovery after spinal cord injury through microglia polarization regulation , 2017, Journal of cellular and molecular medicine.

[21]  Á. Chamorro,et al.  Neuroprotection in acute stroke: targeting excitotoxicity, oxidative and nitrosative stress, and inflammation , 2016, The Lancet Neurology.

[22]  Y. E. Chen,et al.  Angiogenesis-regulating microRNAs and Ischemic Stroke. , 2015, Current vascular pharmacology.

[23]  A. Rabinstein,et al.  New strategies for endovascular recanalization of acute ischemic stroke. , 2013, Neurologic clinics.

[24]  Xiao-Qiang Li,et al.  Neuroprotective Effects of Salidroside and its Analogue Tyrosol Galactoside Against Focal Cerebral Ischemia In Vivo and H2O2-Induced Neurotoxicity In Vitro , 2012, Neurotoxicity Research.

[25]  R. Dal-Ré.  Worldwide clinical interventional studies on leading causes of death: a descriptive analysis. , 2011, Annals of epidemiology.

[26]  K. Furie,et al.  Stroke Treatment Academic Industry Roundtable (STAIR) Recommendations for Maximizing the Use of Intravenous Thrombolytics and Expanding Treatment Options With Intra-arterial and Neuroprotective Therapies , 2011, Stroke.

[27]  Hao Li,et al.  Using Recombinant Tissue Plasminogen Activator to Treat Acute Ischemic Stroke in China: Analysis of the Results From the Chinese National Stroke Registry (CNSR) , 2011, Stroke.

[28]  C. Kleinschnitz,et al.  Experimental & Translational Stroke Medicine Rodent Models of Focal Cerebral Ischemia: Procedural Pitfalls and Translational Problems , 2009 .

[29]  Juan Zhang,et al.  Salidroside protects cardiomyocyte against hypoxia-induced death: a HIF-1alpha-activated and VEGF-mediated pathway. , 2009, European journal of pharmacology.

[30]  A. Hishida.  Determinants for the prognosis of acute renal disorders that developed during or after treatment with edaravone , 2009, Clinical and Experimental Nephrology.

[31]  Li Ma,et al.  [Protective effects of salidroside on oxidative damage in fatigue mice]. , 2009, Zhong xi yi jie he xue bao = Journal of Chinese integrative medicine.

[32]  Myron D. Ginsberg,et al.  Neuroprotection for ischemic stroke: Past, present and future , 2008, Neuropharmacology.

[33]  M. Fisher.  Enhancing the Development and Approval of Acute Stroke Therapies: Stroke Therapy Academic Industry Roundtable , 2005, Stroke.

[34]  Y. Namiki,et al.  Edaravone, a novel radical scavenger, inhibits oxidative modification of low-density lipoprotein (LDL) and reverses oxidized LDL-mediated reduction in the expression of endothelial nitric oxide synthase. , 2005, Atherosclerosis.

[35]  D. DeLong,et al.  Effect of a Novel Free Radical Scavenger, Edaravone (MCI-186), on Acute Brain Infarction , 2003, Cerebrovascular Diseases.

[36]  Stroke Therapy Academic Industry Roundtable.  Recommendations for standards regarding preclinical neuroprotective and restorative drug development. , 1999, Stroke.

[37]  M. Moskowitz,et al.  Pathobiology of ischaemic stroke: an integrated view , 1999, Trends in Neurosciences.

[38]  L. Pitts,et al.  Rat middle cerebral artery occlusion: evaluation of the model and development of a neurologic examination. , 1986, Stroke.

[39]  K. Birmingham.  Future of neuroprotective drugs in doubt , 2002, Nature Medicine.

[40]  F. Tomasello,et al.  Behavioral deficits following experimental subarachnoid hemorrhage in the rat. , 1994, Journal of neurotrauma.